Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Theriva Biologics ( (TOVX) ) is now available.
On October 13, 2025, Theriva Biologics announced the presentation of expanded data from the VIRAGE Phase 2b trial on metastatic pancreatic ductal adenocarcinoma (mPDAC) at the ESMO 2025 Congress. The trial results indicated that patients receiving VCN-01 in combination with standard chemotherapy showed improved overall survival, progression-free survival, and duration of response compared to chemotherapy alone. The administration of VCN-01 was well tolerated, with all related serious adverse events resolved. These findings could enhance Theriva’s positioning in the oncology field by demonstrating the potential efficacy of VCN-01 in treating mPDAC.
The most recent analyst rating on (TOVX) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Theriva Biologics stock, see the TOVX Stock Forecast page.
Spark’s Take on TOVX Stock
According to Spark, TipRanks’ AI Analyst, TOVX is a Neutral.
Theriva Biologics faces substantial financial difficulties with no revenue and growing losses, which is a major concern. While technical indicators show some short-term positive momentum, the long-term trend remains negative. The lack of profitability impacts valuation. However, the recent positive clinical trial results provide a potential future catalyst that could improve the company’s prospects.
To see Spark’s full report on TOVX stock, click here.
More about Theriva Biologics
Theriva Biologics is a diversified clinical-stage company focused on developing therapeutics for cancer and related diseases, particularly in areas with high unmet needs. The company’s lead candidates include VCN-01, an oncolytic adenovirus designed to target tumor cells and improve the efficacy of cancer treatments, and SYN-004, an oral therapy aimed at protecting the gut microbiome during antibiotic treatment to prevent complications in transplant recipients.
Average Trading Volume: 873,646
Technical Sentiment Signal: Sell
Current Market Cap: $4.45M
Learn more about TOVX stock on TipRanks’ Stock Analysis page.